SymBio Pharmaceuticals Limited revised Earnings Forecast for the period from January 1, 2022 to December 31, 2022. For the period, the company now expected net sales of JPY 10,003 million against the previous forecast of JPY 10,003 million, Operating profit of JPY 2,000 million against the previous forecast of JPY 1,770 million, profit attributable to owners of parent of JPY 1,650 million against the previous forecast of JPY 1,480 million and Earnings per share of JPY 42.42 against the previous forecast of JPY 38.35.